Journals / Gülhane Tıp Dergisi / 2021 / Cilt: 63 - Sayı: 4

Vimentin and its role as a biomarker in health and disease

Pages
232–237
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The present review focuses on the structure, functions, clinical implications and future scope of vimentin in the management of various diseases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Vimentin is an intermediate filament protein responsible for maintaining cellular integrity and resistance to stress.
📊
Key Findings & Data:It has a widespread distribution in many cells throughout the body where it forms a cytoskeletal framework.
💡
Conclusion & Impact:The present review focuses on the structure, functions, clinical implications and future scope of vimentin in the management of various diseases.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Vimentin is an intermediate filament protein responsible for maintaining cellular integrity and resistance to stress. It has a widespread distribution in many cells throughout the body where it forms a cytoskeletal framework. Vimentin plays an important role in the regulation of many cellular and tissue functions. It is overexpressed in malignancies, potentially malignant oral disorders and autoimmune conditions like rheumatoid arthritis and Crohn’s disease. It is associated with cell surface binding and replication of viruses such as human immunodeficiency virus (HIV), severe acute respiratory syndrome-related Coronavirus, dengue and encephalitis. In HIV, it is associated with the viral infectivity factor which is associated with HIV replication. It can be used as a biomarker for diagnosis and prognosis and has potential as a therapeutic target in many conditions. The present review focuses on the structure, functions, clinical implications and future scope of vimentin in the management of various diseases.

🔖

Cite This Article

BABU, G. S., HEGDE, S., AJİLA, V., ASAN, M. F., PANDİTA, V. (2022). Vimentin and its role as a biomarker in health and disease. Gülhane Tıp Dergisi, Cilt: 63 - Sayı: 4, 232–237. https://ajindex.com/articles/526788

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Damjanov I. Antibodies to intermediate filaments and histogenesis. Lab Invest. 1982;47:215-217
  2. Ramos I, Stamatakis K, Oeste CL, Pérez-Sala D. Vimentin as a Multifaceted Player and Potential Therapeutic Target in Viral Infections. Int J Mol Sci. 2020;21:4675
  3. Buckley IK, Porter KR. Cytoplasmic fibrils in living cultured cells. A light and electron microscope study. Protoplasma. 1967;64:349-380
  4. Franke WW, Schmid E, Osborn M, Weber K. Different intermediate-sized filaments distinguished by immunofluorescence microscopy. Proc Natl Acad Sci U S A. 1978;75:5034-5038
  5. Perreau J, Lilienbaum A, Vasseur M, Paulin D. Nucleotide sequence of the human vimentin gene and regulation of its transcription in tissues and cultured cells. Gene. 1988;62:7- 16
  6. Parry DA. Hendecad repeat in segment 2A and linker L2 of intermediate filament chains implies the possibility of a right- handed coiled-coil structure. J Struct Biol. 2006;155:370- 374
  7. Herrmann H, Aebi U. Intermediate filaments: molecular structure, assembly mechanism, and integration into functionally distinct intracellular Scaffolds. Annu Rev Biochem. 2004;73:749-789
  8. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68:3033-3046
  9. Valgeirsdóttir S, Claesson-Welsh L, Bongcam-Rudloff E, Hellman U, Westermark B, Heldin CH. PDGF induces reorganization of vimentin filaments. J Cell Sci. 1998;111:1973-1980
  10. Inagaki M, Gonda Y, Ando S, Kitamura S, Nishi Y, Sato C. Regulation of assembly-disassembly of intermediate filaments in vitro. Cell Struct Funct. 1989;14:279-286
  11. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003;112:1776- 1784
  12. Kalluri R, Weinberg RA. The basics of epithelial- mesenchymal transition. J Clin Invest. 2009;119:1420- 1428
  13. Ivaska J. Vimentin: Central hub in EMT induction? Small GTPases. 2011;2:51-53
  14. Gilles C, Polette M, Zahm JM, Tournier JM, Volders L, Foidart JM, et al. Vimentin contributes to human mammary epithelial cell migration. J Cell Sci. 1999;112:4615-4625
  15. Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 2010;24:1838-1851
  16. Liao G, Gundersen GG. Kinesin is a candidate for cross- bridging microtubules and intermediate filaments. Selective binding of kinesin to detyrosinated tubulin and vimentin. J Biol Chem. 1